Skip to main content
N4 PHARMA PLC logo

N4 PHARMA PLC — Investor Relations & Filings

Ticker · N4P ISIN · GB00BYW8QM32 LEI · 213800I841D2RKMFK955 IL Professional, scientific and technical activities
Open in API
Filings indexed 840 across all filing types
Latest filing 2017-03-28 Environmental & Social …
Country GB United Kingdom
Listing IL N4P

About N4 PHARMA PLC

https://n4pharma.com/

N4 Pharma PLC is a specialist pharmaceutical company focused on the development of Nuvec®, its proprietary silica nanoparticle delivery system. This platform technology is designed to enhance the cellular delivery and potency of nucleic acid-based treatments, such as vaccines and cancer therapies. The company's primary focus is on applying Nuvec® to enable advanced therapies for oncology and infectious diseases. N4 Pharma's business model involves developing and out-licensing its technology to pharmaceutical and biotechnology partners to improve the performance of new and existing drugs.

Recent filings

Filing Released Lang Actions
Further US Patent Grant
Environmental & Social Information Classification · 1% confidence The document begins with an 'RNS Number' and is dated March 28, 2017. The content announces a specific corporate event: the granting of a new US Patent (US9,603,828) related to the company's lead product, SFX-01. This is a formal announcement of a material development concerning intellectual property. Since it is a general regulatory announcement distributed via the RNS service and does not fit neatly into specific categories like Earnings Release (ER), Annual Report (10-K), or Director's Dealing (DIRS), the most appropriate classification is the general regulatory filing category.
2017-03-28 English
Services Agreement with QuintilesIMS
Regulatory Filings Classification · 1% confidence The document is identified by the 'RNS Number : 1503A' header and the concluding statement 'This information is provided by RNS The company news service from the London Stock Exchange'. This indicates it is a regulatory announcement disseminated through the Regulatory News Service (RNS). The content describes a strategic clinical development services agreement, which is a material corporate event announcement. Since this is a general regulatory announcement that doesn't fit the specific categories like Director's Dealing (DIRS), Dividend Notice (DIV), or Capital Change (CAP), the most appropriate classification is the general regulatory filing category, RNS.
2017-03-22 English
Posting of Annual report & Notice of AGM
Report Publication Announcement Classification · 1% confidence The document is very short (2865 characters) and explicitly states that the 'Annual Report and Accounts' and the 'Notice of Annual General Meeting' have been posted to shareholders and are available online. It serves primarily to announce the publication and availability of these other documents, rather than being the full report itself. The presence of an RNS Number ('9721Z') and the closing statement 'This information is provided by RNS' strongly suggests a regulatory announcement about the release of other materials. Since it announces the publication of reports (Annual Report and AGM Notice), the most appropriate classification based on the provided definitions and the 'MENU VS MEAL' rule is Report Publication Announcement (RPA). While it mentions the AGM, the primary function here is announcing the availability of the reports, not providing the AGM materials or voting results.
2017-03-20 English
Issue of Equity, PDMR Shareholding and TVR
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document begins with an 'RNS Number' and is dated March 6, 2017. The content explicitly announces an 'Issue of Equity, Director/PDMR Shareholding and Total Voting Rights'. This involves the issuance of new ordinary shares following option exercises by management (PDMRs) and updates the total voting rights denominator. This type of announcement, which deals with changes in share capital structure and insider transactions, fits best under the 'Share Issue/Capital Change' (SHA) or potentially 'Director's Dealing' (DIRS). However, the primary focus is the issuance of new shares and the resulting total voting rights, which is a direct capital structure change. Since the document is a formal regulatory announcement (indicated by RNS) detailing a share issuance, SHA is the most precise fit among the specific options, although DIRS is also relevant due to the PDMR notice. Given the dual nature, SHA covers the capital change aspect, while DIRS covers the insider aspect. Since the issuance of shares is the main action leading to the voting rights update, SHA is chosen. If SHA wasn't available, RNS would be the fallback. The document length is short (3657 chars) and it is a direct announcement, not a detailed report.
2017-03-06 English
PDMR Dealing
Director's Dealing Classification · 1% confidence The document is identified by the 'RNS Number' header and contains details about a transaction involving a person discharging managerial responsibilities (PDMR Dealing). Specifically, it details the purchase of shares by the Chief Executive Officer (Dr. Jan-Anders Karlsson) of Verona Pharma plc. This type of insider transaction report, detailing personal share dealings by directors/executives, directly corresponds to the definition of 'Director's Dealing' (Code: DIRS). Although it is distributed via RNS, the specific content dictates the DIRS classification over the general RNS fallback.
2017-03-02 English
Final Results
Earnings Release Classification · 1% confidence The document is an 'Earnings Release' (ER). It explicitly states 'today announces its audited results for the year ended 31 December 2016', provides financial highlights (loss after tax, loss per share, cash position), and includes clinical/operational highlights. While it mentions that the full annual report will be available on the website, the document itself contains the core financial data and highlights typical of an earnings release, not just a notification of publication. FY 2016
2017-02-27 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.